ST Renfu announced that Yichang Renfu Pharmaceutical, a holding subsidiary of the company, recently received a “Drug Registration Certificate” for bryprazole tablets approved and issued by the State Drug Administration. The drug is mainly used to treat schizophrenia in adults. Yichang Renfu submitted a listing license application in April 2025. Up to now, the project has invested about 18 million yuan in R&D. The national sales volume of the original research products in 2025 is about 9 million yuan. The approval indicates that Yichang Renfu can sell this product domestically, which will enrich the company's product line. Future sales are affected by various factors and are uncertain.
Zhitongcaijing · 1d ago
Share
Listen to the news
ST Renfu announced that Yichang Renfu Pharmaceutical, a holding subsidiary of the company, recently received a “Drug Registration Certificate” for bryprazole tablets approved and issued by the State Drug Administration. The drug is mainly used to treat schizophrenia in adults. Yichang Renfu submitted a listing license application in April 2025. Up to now, the project has invested about 18 million yuan in R&D. The national sales volume of the original research products in 2025 is about 9 million yuan. The approval indicates that Yichang Renfu can sell this product domestically, which will enrich the company's product line. Future sales are affected by various factors and are uncertain.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending